Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Paarth B. Dodhiawala

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6362-5847; OpenAlex author ID A5055334677; NIH RePORTER profile ID 15493755. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
27
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 grant

Papers 8

  1. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  2. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  3. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.02.035↗
  4. The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. First author DOI 10.1126/scitranslmed.abb5445↗
  5. Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor. Co-author DOI 10.3390/cancers13205076↗
  6. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. First author DOI 10.3390/cancers13215481↗
  7. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. First author DOI 10.3390/cancers12092675↗
  8. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-17-1142↗

Grants 1

  1. Targeting oncogenic KRAS to sensitize pancreatic cancer to NK cell immunotherapy F30CA301797↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kian‐Huat Lim · 8 shared papers, 2018–2024 · strength 1.17
  2. Patrick M. Grierson · 4 shared papers, 2018–2024 · strength 0.49
  3. David G DeNardo · 3 shared papers, 2022–2024 · strength 0.43
  4. Sapana Bansod · 2 shared papers, 2021–2024 · strength 0.37
  5. Daoxiang Zhang · 3 shared papers, 2018–2022 · strength 0.34
  6. Ashenafi Shiferaw Bulle · 2 shared papers, 2020–2024 · strength 0.31
  7. William G. Hawkins · 2 shared papers, 2023–2024 · strength 0.29
  8. Li Ding · 2 shared papers, 2023–2024 · strength 0.29
  9. Ryan C Fields · 2 shared papers, 2023–2024 · strength 0.29
  10. Vikas Somani · 2 shared papers, 2022–2024 · strength 0.29
  11. Varintra E. Lander · 2 shared papers, 2022–2023 · strength 0.27
  12. Lin Li · 2 shared papers, 2021–2022 · strength 0.26
  13. Andrea Wang‐Gillam · 2 shared papers, 2018–2024 · strength 0.23
  14. Namrata Khurana · 1 shared paper, 2020 · strength 0.16
  15. Lin Li · 1 shared paper, 2021 · strength 0.16
  16. Faliang Wang · 1 shared paper, 2021 · strength 0.16
  17. Jieya Shao · 1 shared paper, 2021 · strength 0.16
  18. Ramaswamy Govindan Md · 1 shared paper, 2024 · strength 0.15
  19. Graham D. Hogg · 1 shared paper, 2023 · strength 0.14
  20. John M. Baer · 1 shared paper, 2023 · strength 0.14
  21. Chong Zuo · 1 shared paper, 2023 · strength 0.14
  22. Jad I. Belle · 1 shared paper, 2023 · strength 0.14
  23. Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14
  24. C. Alston James · 1 shared paper, 2023 · strength 0.14
  25. Liang‐I Kang · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.